Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Multiple Myeloma 11Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Neoplasm Metastasis 9Leukemia 9Neoplasms 8Myelodysplastic Syndromes 8Hodgkin Disease 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Lymphoma, Non-Hodgkin 7Leukemia, Myeloid, Acute 7Carcinoma, Renal Cell 7Prostatic Neoplasms 6Melanoma 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Recurrence 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hematologic Neoplasms 5Graft vs Host Disease 5Advanced Cancer 5Unspecified Adult Solid Tumor, Protocol Specific 4Primary Myelofibrosis 4Pancreatic Neoplasms 4Neoplasms, Plasma Cell 4Myeloproliferative Disorders 4Lung Neoplasms 4Leukemia, Myelomonocytic, Chronic 4Leukemia, Myeloid, Chronic-Phase 4Glioblastoma 4

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Soft Tissue Neoplasms × Sirolimus × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡